Publication | Closed Access

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

OncologyMedicineAdvanced Solid TumoursImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentAntitumour ActivityImmunotherapyPharmacologyRadiation OncologyAnti-pd-1/ctla-4 Bispecific Antibody